Direxion Daily LLY Bull 2X ETF

ELIL

시가총액 US$2013만

As the largest publicly traded U.S. healthcare enterprise, Eli Lilly & Co. (NYSE:LLY) has historically offered investors a reliable avenue for growth. Indeed, this narrative has been particularly powerful in 2023 and 2024, which saw LLY stock rise from around $360 to approximately $960 in late summer of last year.

2025 has so far been a big year for leveraged ETFs. I wrote a research note on leveraged ETFs earlier this year (read more here) where I discussed some trends in the leveraged ETF market.

Getting stuck in sideways purgatory can leave traders flummoxed. Should they cut bait or ride out the position in hopes that it will eventually trend upwards?

Wall Street delivered mixed-to-downbeat performance last week thanks to Powell's warning of stagflation, rise of auto stocks on policy hopes, NVIDIA's $5.5B hit on export curb and upbeat retail sales.

On Wednesday, Direxion expanded its suite of leveraged and inverse ETF products with the launch of four new funds.  Each of the new Direxion ETFs offers leveraged or inverse exposure to a single stock's daily price performance.